Aristea Therapeutics, Inc.

Scrip asked 30 industry leaders to share their thoughts around what the biopharma industry will do – and what it needs to do – to advance diversity, equity and inclusion (DEI) this year. Their respon

The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs

Venture capital mega-rounds of $100m or more are driving record levels of VC investment in biopharmaceutical companies, and these big financings have not taken a summer break. [Sidebar#SC144714] The l

Fourth quarter financings for biopharmaceutical start-ups totaled $2.73bn, including Relay Therapeutics 's $400m Series C venture capital round and Cerevel Therapeutics LLC 's $350m Series A round.